SI2198007T1 - Farmacevtski sestavki, ki vsebujejo toksoide Clostridium difficile A in B - Google Patents
Farmacevtski sestavki, ki vsebujejo toksoide Clostridium difficile A in B Download PDFInfo
- Publication number
- SI2198007T1 SI2198007T1 SI200831906T SI200831906T SI2198007T1 SI 2198007 T1 SI2198007 T1 SI 2198007T1 SI 200831906 T SI200831906 T SI 200831906T SI 200831906 T SI200831906 T SI 200831906T SI 2198007 T1 SI2198007 T1 SI 2198007T1
- Authority
- SI
- Slovenia
- Prior art keywords
- composition
- sodium
- clostridium difficile
- toxoid
- sucrose
- Prior art date
Links
- 241000193163 Clostridioides difficile Species 0.000 title claims abstract 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- 239000000203 mixture Substances 0.000 claims abstract 29
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 12
- 238000004220 aggregation Methods 0.000 claims abstract 5
- 230000002776 aggregation Effects 0.000 claims abstract 5
- 238000000034 method Methods 0.000 claims abstract 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 11
- 229930006000 Sucrose Natural products 0.000 claims 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 11
- 239000005720 sucrose Substances 0.000 claims 11
- 239000001509 sodium citrate Substances 0.000 claims 9
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 8
- 239000000872 buffer Substances 0.000 claims 6
- 239000001508 potassium citrate Substances 0.000 claims 6
- 229960002635 potassium citrate Drugs 0.000 claims 6
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims 6
- 235000011082 potassium citrates Nutrition 0.000 claims 6
- 229910052708 sodium Inorganic materials 0.000 claims 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 3
- 239000008057 potassium phosphate buffer Substances 0.000 claims 3
- 235000011009 potassium phosphates Nutrition 0.000 claims 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 3
- 239000001488 sodium phosphate Substances 0.000 claims 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 3
- 239000012064 sodium phosphate buffer Substances 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 229910052782 aluminium Inorganic materials 0.000 claims 2
- -1 aluminum compound Chemical class 0.000 claims 2
- XFTWUNOVBCHBJR-UHFFFAOYSA-N Aspergillomarasmine A Chemical compound OC(=O)C(N)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O XFTWUNOVBCHBJR-UHFFFAOYSA-N 0.000 claims 1
- 101000963974 Hydrophis stokesii Alpha-elapitoxin-Ast2b Proteins 0.000 claims 1
- 101000964025 Naja naja Long neurotoxin 3 Proteins 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 239000007979 citrate buffer Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000005187 foaming Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 108700012359 toxins Proteins 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
- Farmacevtski sestavki, ki vsebujejo toksoide Clostridium difficile A in B Patentni zahtevki1. Sestavek, ki vsebuje toksoid Clostridium difficile in farmacevtsko sprejemljive ekscipiente, ki vsebujejo: (a) pufer izbran izmed pufra natrijevega ali kalijevega citrata in pufra natrijevega ali kalijevega fosfata; in (b) sukrozo, kjer farmacevtsko sprejemljivi ekscipienti povečajo termično stabilnost toksoida in/ali zmanjšajo ali odložijo agregacijo toksoida, v primerjavi s sestavkom, ki ne vsebuje omenjenih farmacevtsko sprejemljivih ekscipientov.
- 2. Sestavek po zahtevku 1, ki nadalje vsebuje formaldehid v koncentraciji od 0.001% do 0.020%.
- 3. Sestavek po zahtevku 1 ali 2, kjer: (a) omenjeni farmacevtsko sprejemljivi ekscipienti zmanjšajo ali odložijo agregacijo toksoida za 50% ali več, v primeijavi s sestavkom, ki ne vsebuje omenjenih farmacevtsko sprejemljivih ekscipientov; ali (b) omenjeni farmacevtsko sprejemljivi ekscipienti povečajo termično stabilnost toksoida za 0.5°C ali več, v primerjavi s sestavkom, ki ne vsebuje omenjenih farmacevtsko sprejemljivih ekscipientov.
- 4. Sestavek po kateremkoli zahtevku od 1 do 3, kjer sestavek vsebuje toksoid toksinov C. difficile A in B.
- 5. Sestavek po zahtevku 4, kjer: (a) so toksoidi A in B prisotni v sestavku v razmerju 5:1 (A:B) do 1:5 (A:B); ali (b) so toksoidi A in B prisotni v sestavku v razmerju 3:1 do 3:2 ali 1:1 (A:B).
- 6. Sestavek po kateremkoli zahtevku od 1 do 5, kjer je sestavek farmacevtski sestavek.
- 7. Sestavek po kateremkoli zahtevku od 1 do 6, ki nadalje vsebuje adjuvans.
- 8. Sestavek po zahtevku 7, kjer adjuvans vsebuje aluminijevo spojino, neobvezno, kjer je aluminijeva spojina, spojina aluminijevega hidroksida.
- 9. Sestavek po kateremkoli zahtevku od 1 do 8, kjer je sestavek: (a) v tekoči obliki; ali (b) v obliki suhega praška, liofiliziran, sušen z zamrzovanjem, sušen s pršenjem ali sušen s penjenjem.
- 10. Sestavek po kateremkoli zahtevku od 1 do 9, kjer: (a) je citratni pufer natrijev citrat; ali (b) je fosfatni pufer natrijev fosfat.
- 11. Sestavek po kateremkoli zahtevku od 1 do 9, kjer sestavek vsebuje: (a) toksoide Clostridium difficile A in B, 5-100 mM natrijevega ali kalijevega citrata, 2-20% sukroze in <0.020% formaldehida, pH 5.5-8.5; (b) toksoide Clostridium difficile A in B, 10-30 mM natrijevega ali kalijevega citrata, 2-10% sukroze in <0.020% formaldehida, pH 6.5-8.0; (c) toksoide Clostridium difficile A in B, 20 mM natrijevega citrata, 5% sukroze in 0.016% formaldehida, pH 7.5; (d) toksoide Clostridium difficile A in B, 5-100 mM natrijevega ali kalijevega fosfata, 2- 20% sukroze in <0.020% formaldehida, pH 5.5-8.5; (e) toksoide Clostridium difficile A in B, 10-30 mM natrijevega ali kalijevega fosfata, 2- 10% sukroze in <0.020% formaldehida, pH 6.5-8.0; ali (f) toksoide Clostridium difficile A in B, 20 mM kalijevega fosfata, 5% sukroze in 0.016% formaldehida, pH 7.5.
- 12. Sestavek po kateremkoli zahtevku od 1 do 9, kjer je sestavek v liofilizirani obliki in vsebuje: (a) toksoide Clostridium difficile A in B, 10-30 mM natrijevega ali kalijevega citrata, 2-10% sukroze in <0.020% formaldehida, pH 6.5-8.0; ali (b) toksoide Clostridium difficile A in B, 20 mM natrijevega citrata, 5% sukroze in 0.016% formaldehida, pH 7.5.
- 13. Postopek izdelave sestavka, ki vsebuje toksoid Clostridium difficile in farmacevtsko sprejemljiv ekscipiente, ki vsebujejo: (a) pufer izbran izmed pufra natrijevega ali kalijevega citrata in pufra natrijevega ali kalijevega fosfata; in (b) sukrozo, kjer omenjeni farmacevtsko sprejemljivi ekscipienti povečajo termično stabilnost toksoida in/ali zmanjšajo ali odložijo agregacijo toksoida, v primerjavi s sestavkom, ki ne vsebuje omenjenih farmacevtsko sprejemljivih ekscipientov, kjer postopek obsega zagotavljanje toksoida Clostridium difficile in mešanje omenjenega toksoida Clostridium difficile z omenjenimi farmacevtsko sprejemljivimi ekscipienti.
- 14. Sestavek po kateremkoli zahtevku od 1 do 12, za uporabo v postopku preventive ali zdravljenja okužbe s C. difficile ali bolezni v subjektu.
- 15. Uporaba kombinacije: (a) pufra izbranega izmed pufra natrijevega ali kalijevega citrata in pufra natrijevega ali kalijevega fosfata; in (b) sukroze, za povečanje termične stabilnosti in/ali zmanjšanje ali zavlačevanja agregacija toksoida, Clostridium difficile in vitro. ' ' * **» 4
- 16. Uporaba po zahtevku 15, kjer sta omenjeni komponenti (a) in (b) zagotovljeni v sestavku, kjer je omenjeni sestavek kot je opisano v kateremkoli zahtevku od 1 do 12.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97249607P | 2007-09-14 | 2007-09-14 | |
PCT/US2008/010767 WO2009035707A1 (en) | 2007-09-14 | 2008-09-15 | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
EP08830210.4A EP2198007B1 (en) | 2007-09-14 | 2008-09-15 | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2198007T1 true SI2198007T1 (sl) | 2018-04-30 |
Family
ID=40452372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200831906T SI2198007T1 (sl) | 2007-09-14 | 2008-09-15 | Farmacevtski sestavki, ki vsebujejo toksoide Clostridium difficile A in B |
Country Status (21)
Country | Link |
---|---|
US (3) | US9320790B2 (sl) |
EP (2) | EP2198007B1 (sl) |
JP (3) | JP5503543B2 (sl) |
KR (2) | KR101679812B1 (sl) |
CN (2) | CN101855336B (sl) |
AU (1) | AU2008299885C1 (sl) |
BR (1) | BRPI0816790A8 (sl) |
CA (1) | CA2699435A1 (sl) |
CY (1) | CY1119979T1 (sl) |
DK (1) | DK2198007T3 (sl) |
ES (1) | ES2657485T3 (sl) |
HR (1) | HRP20180054T1 (sl) |
HU (1) | HUE037932T2 (sl) |
IL (1) | IL204366A (sl) |
MX (1) | MX2010002815A (sl) |
NO (1) | NO2198007T3 (sl) |
PL (1) | PL2198007T3 (sl) |
PT (1) | PT2198007T (sl) |
RU (1) | RU2550271C2 (sl) |
SI (1) | SI2198007T1 (sl) |
WO (1) | WO2009035707A1 (sl) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2198007T1 (sl) | 2007-09-14 | 2018-04-30 | Sanofi Pasteur Biologics, Llc | Farmacevtski sestavki, ki vsebujejo toksoide Clostridium difficile A in B |
BR112014004896B1 (pt) | 2010-09-03 | 2023-02-14 | Valneva Usa, Inc. | Polipepttdeo isolado de proteínas de toxina a e toxina b de c. difficile e usos do mesmo |
GB201105981D0 (en) * | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
PE20141029A1 (es) * | 2011-04-22 | 2014-09-04 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
KR101135486B1 (ko) * | 2011-05-25 | 2012-04-13 | 함종욱 | 보툴리눔 에이형 독소의 액상제품 |
BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
CN104903349B (zh) | 2012-11-08 | 2018-10-19 | 十一生物治疗股份有限公司 | Il-6拮抗剂及其应用 |
JP6290918B2 (ja) | 2012-12-05 | 2018-03-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
AP2015008733A0 (en) | 2013-03-14 | 2015-09-30 | Takeda Vaccines Inc | Compositions and methods for live, attenuated alphavirus formulations |
JP2016519671A (ja) | 2013-03-15 | 2016-07-07 | サノフィ パストゥール インコーポレイテッド | トキソイド、組成物および関連方法 |
AU2014228956A1 (en) | 2013-03-15 | 2015-10-08 | Sanofi Pasteur, Inc. | Toxoid, compositions and related methods |
CA2915279A1 (en) | 2013-06-14 | 2014-12-18 | Sanofi Pasteur Inc. | Compositions and methods of immunizing against c. difficile |
WO2014204303A2 (en) | 2013-06-17 | 2014-12-24 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport | Methods for the prevention of aggregation of viral components |
US9930893B2 (en) * | 2014-02-10 | 2018-04-03 | The Johns Hopkins University | Inhibitors of DXP synthase and methods of use thereof |
US11142571B2 (en) | 2014-11-07 | 2021-10-12 | Sesen Bio, Inc. | IL-6 antibodies |
KR20180011784A (ko) | 2015-05-15 | 2018-02-02 | 사노피 파스퇴르 인코포레이티드 | 클로스트리듐 디피실에 대한 면역화 방법 |
BE1023343B1 (nl) * | 2015-05-20 | 2017-02-09 | Mycartis Nv | Opslagbuffer |
CA3012350A1 (en) * | 2016-02-23 | 2017-08-31 | Sesen Bio, Inc. | Il-6 antagonist formulations and uses thereof |
JP7217700B2 (ja) | 2016-09-13 | 2023-02-03 | アラーガン、インコーポレイテッド | 安定化非タンパク質クロストリジウム毒素組成物 |
KR20210010996A (ko) * | 2018-05-21 | 2021-01-29 | 추가이 세이야쿠 가부시키가이샤 | 유리 용기에 봉입된 동결건조 제제 |
WO2021255690A2 (en) * | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4879218A (en) * | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
US5736139A (en) * | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
JPH03193735A (ja) | 1989-12-22 | 1991-08-23 | Shionogi & Co Ltd | グリコペプチド系抗生物質の安定化組成物 |
EP0610295A1 (en) * | 1991-10-16 | 1994-08-17 | Schering Corporation | Lipophilic oligosaccharide antibiotic salt compositions |
WO1994000481A1 (en) | 1992-06-23 | 1994-01-06 | Associated Synapse Biologics | Pharmaceutical composition containing botulinum b complex |
US5562909A (en) | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
US5902565A (en) * | 1993-12-24 | 1999-05-11 | Csl Limited | Spray dried vaccine preparation comprising aluminium adsorbed immunogens |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
JPH08333277A (ja) | 1995-06-05 | 1996-12-17 | Hoechst Japan Ltd | ヒト血液凝固第xiii因子の安定化された水性液製剤 |
JPH11510793A (ja) * | 1995-07-07 | 1999-09-21 | オラバックス インク. | 胃腸病に対する鼻腔内ワクチン接種 |
US5932223A (en) | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
PT892054E (pt) * | 1997-06-20 | 2007-02-28 | Intervet Int Bv | Vacina de clostridium perfringens |
US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
EP1568378B1 (en) * | 1997-10-20 | 2016-03-16 | Sanofi Pasteur Biologics, LLC | Immunization against Clostridium difficile disease |
AU754270B2 (en) * | 1997-10-20 | 2002-11-07 | Sanofi Pasteur Biologics, Llc | Passive immunization against clostridium difficile disease |
US6013635A (en) * | 1998-05-28 | 2000-01-11 | Synsorb Biotech, Inc. | Treatment of C. difficile toxin B associated conditions |
JP2000117967A (ja) * | 1998-10-16 | 2000-04-25 | Fuji Photo Film Co Ltd | インクジェット記録方法 |
FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
KR100922031B1 (ko) * | 1999-04-19 | 2009-10-19 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
US6599715B1 (en) * | 1999-05-12 | 2003-07-29 | The Regents Of The University Of California | Real time viability detection of bacterial spores |
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
EP3192528A1 (en) | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
WO2003088946A1 (en) * | 2002-04-19 | 2003-10-30 | The Regents Of The University Of Michigan | Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens |
US20040235139A1 (en) * | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
JP4671864B2 (ja) | 2003-10-09 | 2011-04-20 | 中外製薬株式会社 | タンパク質溶液の安定化方法 |
CA2799413A1 (en) * | 2004-07-26 | 2006-02-23 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
EP1802349A1 (en) * | 2004-10-13 | 2007-07-04 | Ilypsa, Inc. | Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle |
FR2881139A1 (fr) * | 2005-01-26 | 2006-07-28 | Agronomique Inst Nat Rech | Composition pour la lyophilisation de proteines |
BRPI0613001B8 (pt) | 2005-10-06 | 2021-05-25 | Allergan Inc | composições farmacêuticas de toxina clostrídica estabilizada por uma não-proteína |
US8137677B2 (en) | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
US20090324647A1 (en) * | 2005-10-11 | 2009-12-31 | Borodic Gary E | Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use |
WO2008057550A2 (en) | 2006-11-07 | 2008-05-15 | Sanofi Pasteur Biologics Co. | Stabilization of vaccines by lyophilization |
SI2198007T1 (sl) | 2007-09-14 | 2018-04-30 | Sanofi Pasteur Biologics, Llc | Farmacevtski sestavki, ki vsebujejo toksoide Clostridium difficile A in B |
RU2011126602A (ru) | 2008-12-03 | 2013-01-10 | Берингер Ингельхайм Ветмедика Гмбх | Способ получения вакцин |
-
2008
- 2008-09-15 SI SI200831906T patent/SI2198007T1/sl unknown
- 2008-09-15 PT PT88302104T patent/PT2198007T/pt unknown
- 2008-09-15 RU RU2010114730/10A patent/RU2550271C2/ru not_active IP Right Cessation
- 2008-09-15 BR BRPI0816790A patent/BRPI0816790A8/pt not_active IP Right Cessation
- 2008-09-15 CA CA2699435A patent/CA2699435A1/en not_active Abandoned
- 2008-09-15 EP EP08830210.4A patent/EP2198007B1/en active Active
- 2008-09-15 US US12/677,864 patent/US9320790B2/en active Active
- 2008-09-15 HU HUE08830210A patent/HUE037932T2/hu unknown
- 2008-09-15 DK DK08830210.4T patent/DK2198007T3/en active
- 2008-09-15 PL PL08830210T patent/PL2198007T3/pl unknown
- 2008-09-15 MX MX2010002815A patent/MX2010002815A/es unknown
- 2008-09-15 EP EP16174817.3A patent/EP3124044A1/en active Pending
- 2008-09-15 WO PCT/US2008/010767 patent/WO2009035707A1/en active Application Filing
- 2008-09-15 CN CN200880116603.0A patent/CN101855336B/zh active Active
- 2008-09-15 AU AU2008299885A patent/AU2008299885C1/en not_active Ceased
- 2008-09-15 NO NO08830210A patent/NO2198007T3/no unknown
- 2008-09-15 ES ES08830210.4T patent/ES2657485T3/es active Active
- 2008-09-15 KR KR1020107007994A patent/KR101679812B1/ko active IP Right Grant
- 2008-09-15 KR KR1020157036693A patent/KR20160005378A/ko active IP Right Grant
- 2008-09-15 JP JP2010524889A patent/JP5503543B2/ja active Active
- 2008-09-15 CN CN201610227574.1A patent/CN106039299A/zh active Pending
-
2010
- 2010-03-09 IL IL204366A patent/IL204366A/en active IP Right Grant
-
2013
- 2013-11-22 JP JP2013241821A patent/JP6258674B2/ja active Active
-
2016
- 2016-03-29 US US15/083,428 patent/US9687541B2/en active Active
- 2016-10-31 JP JP2016212540A patent/JP2017052773A/ja active Pending
-
2017
- 2017-06-26 US US15/632,480 patent/US10639362B2/en active Active
-
2018
- 2018-01-11 HR HRP20180054TT patent/HRP20180054T1/hr unknown
- 2018-01-23 CY CY20181100084T patent/CY1119979T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2198007T1 (sl) | Farmacevtski sestavki, ki vsebujejo toksoide Clostridium difficile A in B | |
HRP20210547T1 (hr) | Sastavi koji sadrže konjugate lijeka antitijela-duocarmycin | |
WO2010100200A3 (en) | Lyophilised antibody formulation | |
WO2016184576A3 (en) | Dry powder composition comprising long-chain rna | |
WO2008150479A3 (en) | High temperature stable peptide formulation | |
MX368897B (es) | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos. | |
PH12019502033A1 (en) | Pharmaceutical composition comprising selexipag | |
AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
BRPI0809663A8 (pt) | Composição de vírus vivo atenuado, usos da mesma, métodos de diminuição da inativação de vírus vivo atenuado, e kit para diminuir a inativação de uma composição de vírus vivo atenuado. | |
RU2012125254A (ru) | Составы антитела | |
IN2015DN00888A (sl) | ||
UY29410A1 (es) | Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones. | |
WO2013104995A3 (en) | Compositions and methods for treating viral infections | |
MX344054B (es) | Composicion de oligosacaridos y galactosacaridos de la leche para formula para lactantes que contiene la fraccion soluble de oligosacaridos presente en la leche y que tiene un bajo nivel de monosacaridos y un proceso para producir la composicion. | |
WO2006076620A3 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
MX2008009357A (es) | Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion. | |
WO2010039762A3 (en) | Pharmaceutical compositions comprising boronic acid compounds | |
RU2013128277A (ru) | СТАБИЛЬНЫЕ ИММУНОГЕННЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Staphylococcus aureus | |
BRPI0818541B8 (pt) | composição farmacêutica que compreende grânulos incluindo picossulfato de sódio e bicarbonato de potássio e seu processo para a preparação | |
WO2008049633A8 (en) | Spray-freeze-drying process for the preparation of pellets comprising percolation drying | |
MX2020009935A (es) | Formulaciones acuosas y estables de anticuerpos anti-tau. | |
ZA200905690B (en) | Compositions comprising peg-interferon alpha conjugates and raffinose as cryoprotectant | |
WO2008150275A3 (en) | Methods for preventing and ameiliorating porcine respiratory and reproductive syndrome virus-associated disease by immunizing against porcine ttv infection | |
BR112022022620A2 (pt) | Formulações de anticorpos anti-il-33 | |
WO2009084036A3 (en) | Composition for treatment of viral infections |